Automation Partnerships Leverage the ongoing integration with SPT Labtech to target automation-focused labs and CROs, offering joint solutions that couple Transcreener assays with their Dragonfly platform to accelerate HTS on partner instruments.

Custom Assay Licensing Promote Transcreener HTS as a platform for rapid screening across multiple enzyme families and offer custom assay development and licensing to pharma/biotech customers seeking faster hit generation without bespoke development.

Targeted Disease Partnerships BellBrook's focus on VPS4B ATPase inhibitors, cGAS, and TREX1 HTS assays suggests opportunities for co-development or co-marketing with pharma programs targeting lupus, autoimmune diseases, and related signaling pathways.

Mid-Market Growth With scalable HTS capabilities and growing adoption, pursue mid-sized pharma and CRO partnerships, including OEM licensing or managed screening services to expand BellBrook's customer base beyond early adopters.

Funding Levers Past SBIR funding indicates potential to leverage grant-backed collaborations; propose customer-funded or grant-supported projects that extend BellBrook's assays into new targets, helping clients fund large screening campaigns.